The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. Chiasma disavows any obligation to update the information contained in such press releases after the date of their issuance.
|01/08/18||Chiasma Reports on Significant Progress Made During 2017|
|Initiated CHIASMA OPTIMAL Phase 3 Clinical Trial after SPA agreement with FDA
Announces expected year-end 2017 cash and investments balance of approximately $67 million
Continues to expect existing cash and investments to be sufficient to fund operations through anticipated release of top-line data from CHIASMA OPTIMAL Phase 3 Clinical Trial by the end of 2019
WALTHAM, Mass., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage biopharmaceutical company fo... |
This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent filings with the U.S. Securities and Exchange Commission.